| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/AJG.2010.216 |
| P8608 | Fatcat ID | release_ab3z5yoqwzajlhfmgkoz2pcwmq |
| P698 | PubMed publication ID | 20502446 |
| P50 | author | Tamara Arenovich | Q80161936 |
| P2093 | author name string | E Jenny Heathcote | |
| Teru Kumagi | |||
| Catalina Coltescu | |||
| Gideon M Hirschfield | |||
| Maha Guindi | |||
| Rupert Abdalian | |||
| Sandra E Fischer | |||
| P2860 | cites work | Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment | Q46414837 |
| Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome | Q46852534 | ||
| The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis | Q49110706 | ||
| Incidence, prevalence and clinical course of primary biliary cirrhosis in a Spanish community. | Q51107644 | ||
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis | Q40883127 | ||
| Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid | Q43483632 | ||
| Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients | Q43903202 | ||
| Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis | Q44487597 | ||
| The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis | Q45247238 | ||
| Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis | Q45839711 | ||
| Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid | Q46126105 | ||
| Prognosis in primary biliary cirrhosis: model for decision making | Q46316848 | ||
| Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis | Q46408092 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | primary biliary cholangitis | Q1072420 |
| P304 | page(s) | 2186-2194 | |
| P577 | publication date | 2010-05-25 | |
| P1433 | published in | The American Journal of Gastroenterology | Q7713501 |
| P1476 | title | Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis | |
| P478 | volume | 105 |
| Q48342063 | A brief review on prognostic models of primary biliary cholangitis |
| Q35490131 | A decline of LAMP- 2 predicts ursodeoxycholic acid response in primary biliary cirrhosis |
| Q53591523 | A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. |
| Q36116022 | Advances in pharmacotherapy for primary biliary cirrhosis |
| Q39176767 | Association between serum soluble CD14 and IL-8 levels and clinical outcome in primary biliary cholangitis. |
| Q91431676 | Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis |
| Q33641759 | Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study |
| Q37855976 | Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis |
| Q33723821 | Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients. |
| Q85345310 | Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA |
| Q55324101 | Biomarkers for primary biliary cholangitis: current perspectives. |
| Q26766699 | Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver |
| Q36193470 | Case-control study on prednisolone combined with ursodeoxycholic acid and azathioprine in pure primary biliary cirrhosis with high levels of immunoglobulin G and transaminases: efficacy and safety analysis |
| Q57111104 | Cholestatic liver diseases: new targets, new therapies |
| Q59528257 | Chronische cholestatische Leberkrankheiten |
| Q55394717 | Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis. |
| Q26772310 | Combination antiretroviral studies for patients with primary biliary cirrhosis |
| Q54040784 | Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. |
| Q91644552 | Concomitant Sjögren's Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis |
| Q36752084 | Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis |
| Q57603219 | Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: Results of a 14-year cohort study |
| Q92864604 | Emerging therapies for PBC |
| Q91844615 | Evaluation of the United Kingdom-primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population |
| Q39485889 | Evidence for the association between IgG-antimitochondrial antibody and biochemical response to ursodeoxycholic acid treatment in primary biliary cholangitis |
| Q38849427 | Evidence-based clinical practice guidelines for liver cirrhosis 2015. |
| Q45830237 | Expression of micro-RNAs in peripheral blood mononuclear cells from primary biliary cirrhosis patients |
| Q56971225 | Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis |
| Q35933236 | Functional and structural features of cholangiocytes in health and disease |
| Q47205297 | Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland. |
| Q36682798 | Incidence, mortality, and predictive factors of hepatocellular carcinoma in primary biliary cirrhosis |
| Q92509387 | Incidence, prevalence, and outcome of primary biliary cholangitis in a nationwide Swedish population-based cohort |
| Q38620686 | It is time to change primary biliary cirrhosis (PBC): New nomenclature from "cirrhosis" to "cholangitis", and upcoming treatment based on unveiling pathology |
| Q34043010 | Liver alkaline phosphatase: a missing link between choleresis and biliary inflammation |
| Q39584105 | Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score |
| Q91702707 | Low rate of new-onset primary biliary cholangitis in a cohort of anti-mitochondrial antibody-positive subjects over six years of follow-up |
| Q47787189 | Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome |
| Q47567609 | Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. |
| Q37355843 | Natural history and management of primary biliary cirrhosis |
| Q38261577 | New therapies for primary biliary cirrhosis |
| Q89623998 | New treatments/targets for primary biliary cholangitis |
| Q44966935 | Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis |
| Q42375647 | Novel strategies and therapeutic options for the management of primary biliary cholangitis |
| Q38911238 | Obeticholic acid for the treatment of primary biliary cholangitis |
| Q28072209 | Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection |
| Q38628470 | Obeticholic acid for the treatment of primary biliary cirrhosis |
| Q37963978 | Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis |
| Q34623557 | Pathogenesis of Cholestatic Liver Disease and Therapeutic Approaches |
| Q55192048 | Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis. |
| Q47114292 | Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis |
| Q90707736 | Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases |
| Q39047912 | Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics |
| Q26781780 | Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Review Featuring a Women's Health Perspective |
| Q57141930 | Primary biliary cirrhosis |
| Q38058979 | Primary biliary cirrhosis and bile acids |
| Q26799419 | Primary biliary cirrhosis: From bench to bedside |
| Q43987255 | Primary biliary cirrhosis: proposal for a new simple histological scoring system |
| Q33920325 | Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid |
| Q38174167 | Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis |
| Q26796355 | Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists |
| Q55009231 | Serum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis. |
| Q41009473 | Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein Level Predicts Liver Fibrosis and Prognosis in Primary Biliary Cirrhosis |
| Q48145461 | Serum levels of a cell death biomarker predict the development of cirrhosis-related conditions in primary biliary cholangitis. |
| Q33419647 | Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study |
| Q54714842 | Stratified medicine and primary biliary cholangitis. |
| Q52624982 | The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. |
| Q35942610 | The Cholangiopathies |
| Q41303819 | The Natural History and Prognosis of Primary Biliary Cirrhosis with Clinical Features of Autoimmune Hepatitis |
| Q40681087 | The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. |
| Q26829493 | The diagnosis of primary biliary cirrhosis |
| Q46813053 | The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210. |
| Q88017698 | The therapeutic effect of UDCA is a factor in determining the prognosis of primary biliary cirrhosis |
| Q34342199 | Treatment of autoimmune liver disease: current and future therapeutic options |
| Q39314534 | Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: A systematic review. |
| Q64991757 | Treatment of primary biliary cirrhosis: Is there more to offer than ursodeoxycholic acid? |
Search more.